Iloprost Waymade (Iloprost Trometamol)

Iloprost is a synthetic prostacyclin analog that binds to IP receptors on vascular smooth‑muscle cells, stimulating cyclic AMP production. This leads to vasodilation, reduced pulmonary vascular resistance, and inhibition of platelet aggregation, which together improve blood flow in affected vessels.

The dose of Iloprost Waymade is individualized and set by the prescribing physician based on the patient’s clinical condition, severity of disease, and response to therapy. Specific dosing regimens are not provided here and should follow the prescriber’s instructions.

Safety data for Iloprost in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and import documentation.

Iloprost is a short‑acting prostacyclin analog administered intravenously, offering rapid onset and titratable dosing. Compared with longer‑acting agents such as epoprostenol or treprostinil, Iloprost may require more frequent infusion adjustments but provides flexibility in acute settings and can be used when other prostacyclins are contraindicated.

Iloprost Waymade should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the solution. Keep the product in its original packaging until use to maintain stability and potency.

Iloprost Waymade is given as an intravenous injection or infusion under the supervision of a qualified healthcare professional. The infusion rate and duration are determined by the prescriber, and patients are monitored for blood‑pressure changes and adverse reactions during administration.

Serious risks include severe hypotension, pulmonary edema, significant bleeding, thrombocytopenia, and rare but life‑threatening allergic reactions such as anaphylaxis. Patients should be closely monitored, especially during dose titration and infusion, to detect and manage these events promptly.

Iloprost is contraindicated in patients with active uncontrolled bleeding, severe hypotension, known hypersensitivity to iloprost or any component of the formulation, and in those where prostacyclin therapy is deemed unsafe by the treating physician.